{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choroid&page=12", "query": { "condition": "Choroid", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 280, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choroid&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choroid&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T10:55:19.539Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00084656", "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "Tyrosinase/gp100/MART-1 Peptides", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 77, "start_date": "2004-05-31", "completion_date": "2009-10-31", "has_results": true, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084656" }, { "nct_id": "NCT05024695", "title": "Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glaucoma" ], "interventions": [ { "name": "MINIject™ Implant", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "iSTAR Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "46 Years", "maximum_age": null, "sex": "ALL", "summary": "46 Years and older" }, "enrollment_count": 975, "start_date": "2021-08-19", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 28, "location_summary": "Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chico", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024695" }, { "nct_id": "NCT00766337", "title": "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Sirolimus in combination with ranibizumab", "type": "DRUG" }, { "name": "Placebo in combination with ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 62, "start_date": "2008-12", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00766337" }, { "nct_id": "NCT03865212", "title": "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Choroid Melanoma", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Uveal Melanoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-06-12", "completion_date": "2025-10-12", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03865212" }, { "nct_id": "NCT00089206", "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "multi-epitope melanoma peptide vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 7, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089206" }, { "nct_id": "NCT00100880", "title": "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "perfusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 45, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100880" }, { "nct_id": "NCT00452868", "title": "Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Cognitive/Functional Effects", "Long-term Effects Secondary to Cancer Therapy in Children", "Neurotoxicity", "Psychosocial Effects of Cancer and Its Treatment", "Radiation Toxicity" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 14, "start_date": "2006-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Winston-Salem, North Carolina", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452868" }, { "nct_id": "NCT00533520", "title": "Evaluation of Dosing Interval of Higher Doses of Ranibizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brandon G. Busbee, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "50 Years to 95 Years" }, "enrollment_count": 37, "start_date": "2007-09", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533520" }, { "nct_id": "NCT00733304", "title": "An Extension to Study MD7108240", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 42, "start_date": "2008-06-25", "completion_date": "2009-09-09", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 8, "location_summary": "Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733304" }, { "nct_id": "NCT00071227", "title": "Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Macular Degeneration", "Retinal Vein Occlusion" ], "interventions": [ { "name": "Triamcinolone Acetonide (TAC-PF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2003-10-15", "completion_date": "2007-08-15", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-11-14T10:55:19.539Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071227" } ] }